Kundi Featured on FDA Committee Peptide Vote

The committee’s recommendation, which ran contrary to FDA staff recommendations, are only advisory and don’t affect the legal statuses. 

Abha said that Section 503A solely provides a route for traditional pharmacy compounding and not carte blanch pharmaceutical manufacturing. 

“Getting on the list wouldn’t mean open access,” she said. “Compounders could still only prepare these peptides for a specific patient with a prescription, not stockpile them for general sale.”

“Nothing about the PCAC vote changes the law today,” Abha added. “Until FDA actually finalizes a rule adding a substance to the 503A Bulks List, these peptides still don’t meet any of the three legal pathways into compounding: no monograph, no status as a component of an approved drug, and no listing.”

During the FDA’s rulemaking process, companies that begin marketing or dispensing unapproved compounded peptides run the risk of FDA enforcement. 

“The period before a final rule isn’t necessarily an open runway,” Abha said. “It could come with real strings attached, and firms betting on unrestricted room to operate… may find that assumption doesn’t hold up.”

Even if the compounded products are FDA approved, marketing language can still open companies to FDA and Federal Trade Commission (FTC) scrutiny. 

Both the FDA and the FTC consider the overall impression created by marketing rather than inspecting each word in splendid isolation, Abha said.

“It’s not mechanism language versus disease language as two clean categories, it’s whether the overall message, including tone and imagery, ends up implying a treatment or outcome claim regardless of the words chosen.”

The more consequential issue is whether the FDA will follow the committee recommendations or listen to the agency’s scientific reviewers, who voted against approving all seven peptides. 

Abha noted that the committee has no legal mechanism to force the FDA’s approval process. But if the agency ultimately follows the panel over its own scientific staff this time, she said the reasoning will matter.

“Well-established administrative law principles generally require an agency to reasonably explain its decisions and to engage with conflicting evidence in its own record,” she said. 

A final rule that failed to address the staff position could attract legal challenges and potentially make the policy less durable. 

Abha said that the market itself, including licensed compounders, wellness clinics, and online platforms, is introducing a different level of complexity to the approval process. 

“A few things are colliding,” she said. “That mix of contested data, scattered sales channels, political pressure pulling in opposite directions, and a booming market that shows no sign of slowing down is what makes this so hard to regulate cleanly.”

Read the full article here.